Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Managing hypertension in patients with renal disease and diabetes

Alan Bell
CMAJ May 30, 2000 162 (11) 1555-1556;
Alan Bell
Family physician Downsview, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

I congratulate the authors of the 1999 Canadian recommendations for the management of hypertension1 for their diligent work, but question the recommendations regarding hypertensive patients with diabetic and nondiabetic renal disease. Ample evidence exists to support the use of angiotensin-converting- enzyme (ACE) inhibitors as first-line agents in both of these circumstances, but the selection of dihydropyridine calcium-channel blockers as an alternative therapy for nondiabetic renal disease and the lack of a recommendation for the use of nondihydropyridines in diabetic nephropathy are questionable.

A number of well-designed studies have demonstrated that the reduction of proteinuria and preservation of renal function by nondihydropyridines, particularly verapamil, is similar to that by ACE inhibitors in diabetic nephropathy.2,3,4 These studies further indicate that the reduction of proteinuria by nondihydropyridines is additive to the effect of ACE inhibitors.

In contrast, studies using dihydropyridines have failed to demonstrate a benefit with regard to proteinuria or renal function unless systolic blood pressure is reduced below 110 mm Hg.5 Furthermore, several trials have demonstrated a renal hazard associated with the use of dihydropyridines in diabetic nephropathy and other situations. Isradipine was associated with a 50% increase in proteinuria in African Americans with diabetic nephropathy.6 In the PRAISE trial 7.7% of subjects randomized to receive amlodipine had worsening renal function compared with 3.6% in the placebo group.7

The guidelines cite studies by Bianchi and colleagues and Zucchelli and colleagues in support of the recommendation for the use of dihydropyridines in nondiabetic renal failure.8,9 Although in these 2 studies an ACE inhibitor and a dihydropyridine produced similar changes in renal function, the effects with respect to proteinuria and renal death were significantly better with the ACE inhibitor.

Loss of renal autoregulation has been suggested as one mechanism for the unfavourable effects seen with the dihydropyridines.10 Because nondihydropyridine calcium-channel blockers do not impair renal autoregulation,11 have a favourable effect on glomerular permeability and have been demonstrated to be renal protective in clinical studies previously cited, they may be a better choice as an alternative therapy in diabetic and nondiabetic nephropathy and perhaps in all diabetic patients with hypertension.

Competing interests: Dr. Bell serves as a medical consultant to Searle Canada; he has received speaker fees and travel assistance grants.

References

  1. 1.↵
    Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, et al, for the Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. 1999 Canadian recommendations for the management of hypertension. CMAJ 1999;161(12 Suppl):S1-22.
  2. 2.↵
    Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912-9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997;12:2244-50.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997;8:793-8.
    OpenUrlAbstract
  7. 7.↵
    Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-14.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects on enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991;11:131-7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparision between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996;27:34-41.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Maki DD, Ma JZ, Louis TA, Kasiske BL. Effects of antihypertensive agents on the kidney. Arch Intern Med 1995;155:1073-82.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 162, Issue 11
30 May 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Managing hypertension in patients with renal disease and diabetes
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Managing hypertension in patients with renal disease and diabetes
Alan Bell
CMAJ May 2000, 162 (11) 1555-1556;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Managing hypertension in patients with renal disease and diabetes
Alan Bell
CMAJ May 2000, 162 (11) 1555-1556;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Moving surgical care out of hospitals to reduce wait times
  • Coexisting failures do not diminish the stature of a giant
  • Dare we hope
Show more Letters

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire